Zeus Capital advises on third transaction for 4D pharma
Zeus Capital has advised 4D pharma for the third time in the last year, helping the company to raise £34.75m through the conditional placing of 8,475,610 new ordinary shares.
The Manchester based company successfully floated on AIM in February 2014, raising £16.5m, with a secondary fundraise of £21.5m in July 2014. Both of these transactions were also advised by Zeus. Since its stock market listing, the shares have performed well and the company had a market capitalisation of c. £240m prior to the latest placing.
In recent months, the company has focused its interests solely in the microbiome field and the discovery and development of bacteria as live biotherapeutics.
Dan Bate, Corporate Finance Director at Zeus Capital commented:
"We are delighted to have been able to help 4D Pharma with its further fundraising as it continues to develop and broaden its work in the microbiome field. This is an exciting time for the company and we look forward to seeing the continued progress of its expanding pipeline of live biotherapeutics."
Duncan Peyton, Chief Executive Officer at 4D pharma commented:
"We are delighted to have successfully raised these funds through both existing and new investors. We would like to thank existing investors for their continued support and encouragement, and we welcome our new investors to the company. This is an incredibly exciting time for 4D as it looks to progress its work in the microbiome field."